honglouwawa/iStock via Getty Images Vertex Pharmaceuticals ( NASDAQ: VRTX ) raised its 2024 product revenue guidance range after releasing Q3 financial results that beat on both lines . The company is now forecasting full-year product revenue of $10.8B to $10.
9B, up from $10.65B to $10.85B.
The consensus revenue estimate is $10.76B..